

**Dr Stuart More, MBBCh(Wits), FCNP(SA), MMED  
PhD Candidate**

---

**Contact details:**

**Landline:+27 21 404 4169/Mobile:+27 61 406 8303**

**Email: [stuart.more@uct.ac.za](mailto:stuart.more@uct.ac.za) / [stuartmore.nucmed@gmail.com](mailto:stuartmore.nucmed@gmail.com)**

**Biographical Information**

Full Name: Stuart Setjhaba More  
Current position: Head of Division: Nuclear Medicine and Molecular Imaging University of Cape Town (UCT) and Groote Schuur Hospital/Red Cross War Memorial Children's Hospital

**Qualifications**

- PhD Medical Nuclear Sciences (currently enrolled since 2020), University of Pretoria current
- Master's in Medicine (Nuclear Medicine), University of Cape Town 2018
- Fellow of the College of Nuclear Physicians, College of Medicine South Africa 2017
- Bachelor of Medicine and Surgery, University of the Witwatersrand (Equivalent: MD) 2008
- Matric, St Benedict's College, Bedfordview 2001

**Appointments**

- Editorial Board, Clinical and Translational Imaging 2022 - current
- Head of Division, Nuclear Medicine, Groote Schuur Hospital 03/2024
- Acting Head of Division, Nuclear Medicine, Groote Schuur Hospital 2021 - Feb2024
- Specialist, Groote Schuur Hospital 2019 -Feb2021
- Specialist, Red Cross War Memorial Children's Hospital 2018 - 2019
- Medical Officer, Red Cross War Memorial Children's Hospital 2017 - 2018
- Registrar, Red Cross War Memorial Children's Hospital (Equivalent: Resident) 2013 - 2017
- Medical officer, Internal Medicine, Khayelitsha District Hospital 2012 - 2013
- Medical officer, Emergency Medicine, Paarl Hospital 2011 - 2012
- Community service officer, Eerste River Hospital 2010 - 2011
- Medical Intern, Groote Schuur Hospital 2008 - 2010

**COMMITTEE INVOLVEMENT AND PROFESSIONAL MEMBERSHIP**

**External**

- Immediate Past President, South African Society of Nuclear Medicine (Sept 2023 to present)
- President, South African Society of Nuclear Medicine (2021 - 2023)
- Vice President, South African Society of Nuclear Medicine (2018 - 2021)
- Executive Council Member, Association of Nuclear Physicians (2021 to present)
- Director of Communications, South African Clinician Scientists Society (2018 to present)

- Medical and Scientific Advisory Council: South African Haemophilia Foundation – Nuclear Medicine Portfolio Head (2020 to current)
- Nuclear Medicine Global Initiative (2022 to current)
- South African Medical Association – branch member (2011 to present)

### Academic

- Member of Faculty of Health Sciences Research Committee
- Member of the Faculty of Health Sciences research Committee, University of Cape Town
- Member of Departmental Research Committee, Department of Radiation Medicine, University of Cape Town
- Member and Co-Chair of the Department of Radiation Medicine Transformation Committee, University of Cape Town
- Member of the College of Nuclear Physicians, College of Medicine of South Africa

### Professional

- Health Professions Council of South Africa
- Medical Protection Society
- Society of Nuclear Medicine and Molecular Imaging
- European Association of Nuclear Medicine
- Radiology Society of North America (RSNA)
- World Association of Radiopharmaceutical and Molecular Therapy
- National Osteoporosis Foundation of South Africa
- International Centres for Precision Oncology

### PUBLICATIONS & RESEARCH (click [here](#))

1. Lawal, I.O., Abubakar, S.O., Ndlovu, H. et al. Advances in Radioligand Theranostics in Oncology. *Mol Diagn Ther* 28, 265–289 (2024). <https://doi.org/10.1007/s40291-024-00702-4>
2. Kolade OU, Brink A, Ayeni AO, More S, Holness J. Optimizing PSMA scintigraphy for resource limited settings - a retrospective comparative study. *Cancer Imaging*. 2024 Apr 1;24(1):46. doi: 10.1186/s40644-024-00693-9.
3. Kleynhans J, Summers B, Sakr T, Zeevaart JR, Lundie M, du Plessis S, Mosima L, Bentaleb N, Ekoume FP, Hlongwa K, Shambel S, Mldophane A, Mangatha A, More S. Spotlight: the status of radiopharmacy in Africa. *Clin Transl Imaging Clin Transl Imaging* (2023). <https://doi.org/10.1007/s40336-023-00594-0>
4. Hlongwa K, Kolade O, Alnabulsi A, Steyn R, Brink A, Prasad V, More S. Case report: Peptide receptor radioligand therapy in metastatic pediatric neuroendocrine tumors. *Front. Nucl. Med.* 3:1193880. doi: 10.3389/fnume.2023.1193880
5. Mpanya D, Sathekege M, Klug E, Damelin J, More S, Hadebe B, Vorster M and Tsabedze N (2023) Gallium-68 fibroblast activation protein inhibitor positron emission tomography in cardiovascular disease. *Front. Nucl. Med.* 3:1224905. doi: 10.3389/fnume.2023.1224905
6. Bolcaen J, Combrink N, Spoormans K, More S, Vandevoorde C, Fisher R and Kleynhans J (2023) Biodosimetry, can it find its way to the nuclear medicine clinic?. *Front. Nucl. Med.* 3:1209823. doi: 10.3389/fnume.2023.1209823

7. Abubakar S, More S, Tag N, Olabinjo A, Isah A, Lawal I. Differences in Tumour Aggressiveness Based on Molecular Subtype and Race Measured by [18F]FDG PET Metabolic Metrics in Patients with Invasive Carcinoma of the Breast. *Diagnostics (Basel)*. 2023;13(12):2059. doi:10.3390/diagnostics13122059
8. Urbain J-L, Scott AM, Lee ST, Buscombe J, Weston C, Hatazawa J, Kinuya S, Singh B, Haidar M, Ross A, Lamoureux F, Kunikowska J, Wadsak W, Dierckx R, Paez D, Giammarile F, Lee KH, Hyun J O, Modiselle M, Louw L, More S, Nadel H, Lee D, Wahl R. Theranostic Radiopharmaceuticals: A Universal Challenging Educational Paradigm in Nuclear Medicine. *Journal of Nuclear Medicine*. 2023;64(6):986-91.
9. More S, Naiker T, Jacobs N, Oompie F, Prasad V. Short-Interval, Low-Dose [177 Lu]Lu-Prostate-Specific Membrane Antigen in the Treatment of Refractory Glioblastoma. *Clin Nucl Med*. 2023;48(5):e217-e218. doi:10.1097/RLU.0000000000004612
10. Brink, A.; Hlongwa, K.N.; More, S. The Impact of PET/CT on Paediatric Oncology. *Diagnostics* 2023, 13, 192. <https://doi.org/10.3390/diagnostics13020192>
11. Kolade OU, Ayeni AO, Brink A, Steyn R, More S, Prasad V. SARS-CoV-2 vaccination site as possible pitfall on somatostatin receptor imaging. *Clin Transl Imaging*. 2022;10(6):579-585. doi:10.1007/s40336-022-00519-3
12. Einstein AJ, Hirschfeld C, Williams MC, et al. Worldwide Disparities in Recovery of Cardiac Testing 1 Year Into COVID-19. *J Am Coll Cardiol*. 2022;79(20):2001-2017. doi:10.1016/j.jacc.2022.03.348
13. More S, Marakalala MJ, Sathekge M. Tuberculosis: Role of Nuclear Medicine and Molecular Imaging With Potential Impact of Neutrophil-Specific Tracers. *Front Med (Lausanne)*. 2021 Dec 10;8:758636. doi: 10.3389/fmed.2021.758636. PMID: 34957144; PMCID: PMC8703031.
14. Kudo T, Lahey R, Hirschfeld CB, et al. Impact of COVID-19 Pandemic on Cardiovascular Testing in Asia: The IAEA INCAPS-COVID Study. *JACC Asia*. 2021;1(2):187-199. Published 2021 Sep 21. doi:10.1016/j.jacasi.2021.06.002
15. Mpanya, D., Ayeni, A., More, S. Choncho B, Sathekge M, Tsabedze N. The clinical utility of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in guiding myocardial revascularisation. *Clin Transl Imaging* 10, 9–22 (2022). <https://doi.org/10.1007/s40336-021-00454-9>
16. Yunusa, G.H., Kaoje, A.U., Orunmuyi, A.T., More SS, Jawa ZM, Khalid A. Comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer: a protocol for systematic review and meta-analysis. *Egypt J Radiol Nucl Med* 52, 179 (2021). <https://doi.org/10.1186/s43055-021-00562-6>
17. Hirschfeld CB, Shaw LJ, Williams MC, Lahey R, Villines TC, Dorbala S, Choi AD, Shah NR, Bluemke DA, Berman DS, Blankstein R, Ferencik M, Narula J, Winchester D, Malkovskiy E, Goebel B, Randazzo MJ, Lopez-Mattei J, Parwani P, Vitola JV, Cerci RJ, Better N, Raggi P, Lu B, Sergienko V, Sinitsyn V, Kudo T, Nørgaard BL, Maurovich-Horvat P, Cohen YA, Pascual TNB, Pynda Y, Dondi M, Paez D, Einstein AJ; INCAPS-COVID Investigators Group. Impact of COVID-19 on Cardiovascular Testing in the United States Versus the Rest of the World. *JACC Cardiovasc Imaging*. 2021 Sep;14(9):1787-1799. doi: 10.1016/j.jcmg.2021.03.007. Epub 2021 Jun 16. PMID: 34147434; PMCID: PMC8374310.
18. Van Heerden J, Kruger M, Esterhuizen TM, Du Plessis J, Engelbrecht G, Janse van Vuuren M, van Emmenes B, Uys R, Burger C, Nyakale N, More S, Brink A. The Association between Tumour Markers and Meta-iodobenzylguanidine Scans in South African Children with High-risk Neuroblastoma. *Clin Oncol (R Coll Radiol)*. 2021;33(8):517-526. doi:10.1016/j.clon.2021.03.003
19. Einstein AJ, Shaw LJ, Hirschfeld C, et al. International Impact of COVID-19 on the Diagnosis of Heart Disease [published correction appears in *J Am Coll Cardiol*. 2021 Jul 6;78(1):93]. *J Am Coll Cardiol*. 2021;77(2):173-185. doi:10.1016/j.jacc.2020.10.054

20. Chilwesa PM, Gameldien R, Steyn R, More S, Malherbe F, Human G, et al. Comparison of 18F Fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging for locally advanced breast cancer staging: A prospective study from a tertiary hospital cancer centre in the Western Cape. *South African Journal of Oncology*, 4, 8 pages. doi:<https://doi.org/10.4102/sajo.v4i0.106>
21. Adefuye AO, Adeola HA, More S, Mohamed Z. The need for nationally accepted guidelines for undergraduate nuclear medicine teaching in MBChB programmes in South Africa. *SA J Radiol*. 2020 Jul 28;24(1):1874. doi: 10.4102/sajr.v24i1.1874. PMID: 32832118; PMCID: PMC7433223.
22. More SS, Lazarus J, Brink A. Renal cortical transit time as a predictor for pyeloplasty in pediatric patients with unilateral hydronephrosis. *World J Nucl Med*. 2020 Aug 22;19(4):341-346. doi: 10.4103/wjnm.WJNM\_11\_20. PMID: 33623502; PMCID: PMC7875046.

#### **Post-Graduate Research Supervision(Masters Degrees):**

- Assessing the role of maternal tachycardia as a predictor for possible pulmonary embolism on V/Q scans in pregnant patients
- Diagnosis of CTEPH in patients with Pulmonary Hypertension: comparison of CTPA and V/Q SPECT. A Report from The Groote Schuur Hospital Pulmonary Hypertension Registry.
- A Retrospective Review of Nuclear Medicine Imaging in the Staging of High-intermediate Risk to High Risk Prostate Cancer Patients at Groote Schuur Hospital (
- Diagnostic Accuracy of Bombesin Based PET/CT imaging in Biochemical Recurrence - a systematic review
- Optimizing Bone and [99mTc]Tc-PSMA Scintigraphy Imaging Protocols for Prostate Cancer in Resource Limited Settings
- Impact of Impact of pharmacogenomics on management of patients with metastatic prostate cancer requiring radionuclide therapy
- A dissection and angiographic study of anatomical variations in the anterior communicating artery complex in a South African sample(Study by Ms Mbali Madolo, towards a Master of Science (Human Biology))

## **CLINICAL TRIAL INVOLVEMENT**

Clinical Trial Name:

A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With <sup>177</sup>Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin (GEP-NET) - ongoing

Role: Principal Investigator

Clinical Trial Name: The utility of Rhenium 188 1-Hydroxyethylidene-1,1- diphosphonic acid (HEDP) in bone pain palliation - ongoing

Role: Principal Investigator